Through this Alnylam-funded program, Invitae will perform free testing for US patients suspected to have hereditary ATTR amyloidosis or a family history of it.
The court found that the university had failed to demonstrate that one of its researchers had collaborated with the IP's inventors and therefore is not entitled to co-inventorship.
The firm also said it aims to soon begin human studies for its hepatic porphyria treatment ALN-AS1 and to select a development candidate for its program in primary hyperoxaluria type 1.
The drug is designed to silence complement component C5, whose loss is associated with an attenuated immune response against certain infections.
The proceeds will be used to advance its drug candidates and for general corporate purposes.
The arrangement includes exclusive rights to certain disease targets and non-exclusive rights to platform technologies.
Advances in human genetics and siRNA delivery have helped drive the programs, according to company officials.
Both drugs are administered subcutaneously using Alnylam's GalNAc conjugates.
The therapy is the company's first to feature an optimized version of its GalNAc conjugate delivery technology.
The trial will include both healthy volunteers and patients with paroxysmal nocturnal hemoglobinuria.
Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.
Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.
China is embracing preimplantation genetic diagnosis, Nature News reports.
In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.